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ApoptosisAnti-apoptotic Bcl-2 family proteins have been reported to play an important role in apoptotic cell death of
human malignancies. The aim of this study was to delineate the mechanism of anti-apoptotic Bcl-2 family pro-
teins in pancreatic cancer (PaCa) cell survival. We ﬁrst analyzed the endogenous expression and subcellular lo-
calization of anti-apoptotic Bcl-2 family proteins in six PaCa cell lines by Western blot. To delineate the
functional role of Bcl-2 family proteins, siRNA-mediated knock-down of protein expression was used. Apoptosis
was measured by Cell Death ELISA and Hoechst 33258 staining. In the results, the expression of anti-apoptotic
Bcl-2 family proteins varied between PaCa cell lines. Mcl-1 knock-down resulted in marked cleavage of PARP
and induction of apoptosis. Down-regulation of Bcl-2 or Bcl-xL had a much weaker effect. Simultaneous knock-
down of Bcl-xL and Mcl-1 strongly induced apoptosis, but simultaneous knock-down of Bcl-xL/Bcl-2 or Mcl-1/
Bcl-2 had no additive effect. The apoptosis-inducing effect of simultaneous knock-down of Bcl-xL and Mcl-1
was associatedwith translocation of Bax from the cytosol to themitochondrial membrane, cytochrome c release,
and caspase activation. These results demonstrated that Bcl-xL and Mcl-1 play an important role in pancreatic
cancer cell survival. Targeting both Bcl-xL and Mcl-1 may be an intriguing therapeutic strategy in PaCa.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Of all gastrointestinal carcinomas, pancreatic cancer (PaCa) has the
most unfavorable prognosis. Surgical resection is the only possible cura-
tive treatment for PaCa, but the 5-year survival rate of all patients is
below5% [1]. One reason for thenotoriously dismal prognosis of pancre-
atic cancer is the resistance to currently available chemotherapeutic
drugs. Although gemcitabine has been the approved drug of choice
in the treatment of pancreatic cancer, its efﬁcacy is weak and the im-
provement of overall survival is marginal. Anti-apoptotic members of
the Bcl-2 protein family are often over-expressed in human cancers
and are thought to mediate the resistance to chemotherapeutic drugs.
Thus, a better understanding of the anti-apoptotic mechanisms and
the development of potent and non-toxic strategies to overcome the
pro-survival mechanisms in PaCa cells are of utmost importance to
improve the outcome of PaCa patients.id Geffen School of Medicine at
A 90095, USA. Tel.: +1 310 825
ights reserved.We previously reported that the polyphenol baicalein induced
apoptosis through down-regulation of Mcl-1 in PaCa cells [2]. Mcl-1 is
one of the anti-apoptotic Bcl-2 family proteins. The Bcl-2 family protein
consists of anti-apoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1) and pro-
apoptotic proteins that include multi-domain molecules Bak and Bax,
and the BH3-only proteins Bad, Bid, Bim, Puma, and Noxa [3]. Oligomer-
ization of multi-domain molecules Bak and Bax is the key event on apo-
ptosis; once oligomerization of Bak or Bax occurred, cytochrome c is
released from the mitochondrial outer membrane to the cytosol,
where it binds to apoptotic protease-activating factor-1 (APAF-1) and
caspase-9, thereby activating the caspase activation cascade [4]. Since
anti-apoptotic Bcl-2 family proteins can stabilize Bak or Bax activation,
anti-apoptotic Bcl-2 family proteins are recognized as importantmedia-
tors of cell death. Recently, the anti-apoptotic proteins Bcl-xL andMcl-1,
but not Bcl-2, have been reported to cooperatively protect cells from
death stimuli in several cancer models [5,6]. The importance of Bcl-xL
and Mcl-1 on drug-induced apoptosis is increasingly recognized, but
very little is known about their role in PaCa.
Here, we show that simultaneous knock-down of Bcl-xL and Mcl-1
robustly induced apoptosis through the Bax pathway in PaCa cells.
These data provide the basis for future mechanistic studies on the role
of Bcl-2 family proteins in PaCa and may help to develop novel thera-
peutic strategies aiming at the Bcl-xL/Mcl-1 pathway.
Fig. 1. Endogenous expression of anti-apoptotic Bcl-2 family proteins. Mitochondrial
membrane fraction and cytosolic fraction were separated as described in Materials
and methods, after which anti-apoptotic Bcl-2 family protein expression of BxPC-3
(B), HPAF-II (H), MIA PaCa-2 (M), Panc-1 (P), Capan-2 (C), and AsPc-1 (A) cells were mea-
sured by Western blot. Cox IV (cytochrome oxidase IV) served as loading control for mito-
chondrial membrane fraction. Results are representative of three independent experiments.
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2.1. Reagents
Antibodies against caspase-3, cleaved caspase-3, caspase-7, cleaved
caspase-7, PARP, cleaved-PARP, Bcl-2, Bcl-xL, Mcl-1, Bax, cytochrome c,
cytochrome c oxidase subunit IV (cox-IV), and GAPDH were purchased
from Cell Signaling Technology, Inc. (Danvers, MS). The pan-caspase in-
hibitor zVAD-fmk was from Calbiochem (Darmstadt, Germany). Other
reagents were from common commercial sources.
2.2. Cell culture
The human PaCa cell lines, BxPC-3, HPAF-II, Capan-2, AsPC-1, MIA
PaCa-2, and Panc-1 were obtained from the American Type Culture Col-
lection (ATCC, Rockville, MD) and cultured as described previously [7].
2.3. Transfection of siRNA
siGENOME SMARTpool against Bcl-2, Bcl-xL, Mcl-1, and Bax as well as
siGENOME Non-Targeting Pool (#2) were purchased from Dharmacon
(Lafayette, CO). One day before siRNA transfection, cells were seeded
into 6-well tissue culture plates and incubated overnight at 37 °C with-
out antibiotics. Cells were transfectedwith siRNA (ﬁnal concentration of
20 nM) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer's instructions. Five hours after transfection, medi-
umwas changed to serum free DMEMor RPMI and cells were incubated
for another 24 h.
2.4. DNA fragmentation assay
DNA fragmentation was measured as described previously [8]. Brief-
ly, cells (5 × 105) were transfected with siRNA targeting Bcl-2, Bcl-xL,
Mcl-1, and their combinations. DNA fragmentation was analyzed using
the Cell Death Detection ELISAPlus kit (Roche) according to the
manufacturer's instructions. The extent of apoptosis was presented as
a fold (mU of the treated cells/mU of the non-treated cells).
2.5. Hoechst 33258 staining
To assess changes in nuclear morphology during apoptosis, staining
using ﬂuorescent Hoechst 33258 (Invitrogen, Carlsbad, CA) was per-
formed. Cells were seeded into Lab-Tek® II Chamber Slide™ System
(Nalgene Nunc International, Naperville, IL) and incubated overnight at
37 °C. Medium was changed to serum-free condition. Cells were
transfected with Bcl-xL and Mcl-1 siRNA or control siRNA as described
above, ﬁxed with 4% paraformaldehyde in PBS for 30 min at room tem-
perature, and stained with Hoechst 33258 for 15 min. Slides were
mounted with VECTASHIELD (Vector Laboratories Inc., Burlingame,
CA), andwere observed under aﬂuorescencemicroscope (Nikon, Eclipse
90i, Tokyo, Japan). Apoptotic nuclei were identiﬁed by morphologic
changes such as chromatin condensation and nuclear fragmentation.
2.6. Cell lysates
Total cell lysates were collected as described previously [9]. Protein
concentrationwasmeasured by the BCA Protein Assay Kit (Pierce, Rock-
ford, IL). For preparation of mitochondrial and cytosolic fractions, we
used a mitochondria extraction kit (Pierce) according to the manufac-
turer's instructions. Cells were re-suspended in lysis buffer, and then
disrupted by 80 strokes with a Dounce homogenizer. Homogenates
were centrifuged at 1000 ×g for 10 min to pellet nuclei and cell debris.
Supernatants were subsequently centrifuged at 16,000 ×g for 15 min,
and the cytosolic fractions (supernatants) were collected. Pellets
(heavy membranes enriched with mitochondria) were lysed in RIPA
buffer. To determine the quality of cytosolic and mitochondrialseparation, both fractions were assessed by immunoblotting for the
mitochondrial marker cox-IV.
2.7. Western blot analysis
Western blot was performed as described previously [10]. Brieﬂy, an
equal amount of protein was fractionated on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes (Bio-Rad, Hercules, CA). Membranes were incubated with
5% skim milk in TBS-T (0.1% Tween 20) for 1 h at room temperature
to block nonspeciﬁc binding and incubated with speciﬁc primary anti-
bodies in TBS-T containing 3% skim milk overnight at 4 °C. Proteins
were detected using horseradish peroxidase-conjugated secondary
antibodies (Pierce). Protein–antibody complexes were visualized with
the SuperSignal West Pico Chemiluminescent Substrate or with the
SuperSignal West Femto Chemiluminescent Substrate (Pierce).
2.8. Statistical analysis
Data are presented asmeans ± SD, and statistical comparisonswere
made using the Student's t test for paired observations. Comparisons of
more than two groups were made by a one-way ANOVA with post hoc
Holm–Sidak analysis for pairwise comparisons and comparisons versus
control. An alpha value of 0.05 was used to determine signiﬁcant differ-
ences. All statistics were done in SigmaStat 3.1 (Systat Software, Inc.).
3. Results
3.1. Endogenous expression of anti-apoptotic Bcl-2 family proteins in PaCa
Since the anti-apoptotic Bcl-2 family proteins play amajor role in the
protection against DNA damage-induced apoptosis via the mitochon-
drial pathway [11,12], we ﬁrst sought to determine the endogenous ex-
pression of anti-apoptotic Bcl-2 family proteins in PaCa cell lines.
Mitochondrial and cytosolic fractions were collected after 24 h serum
deprivation. Subcellular fractionation demonstrated that Bcl-2, Bcl-xL,
and Mcl-1 proteins are mainly located at the mitochondrial membrane
in untreated PaCa cells (Fig. 1). The expression of anti-apoptotic
proteins (Bcl-2, Bcl-xL, and Mcl-1) varied between six PaCa cell lines.
Bcl-2 was expressed in MIA PaCa-2 and Panc-1 cells, but virtually
undetectable in other cell lines. Bcl-xL was almost equally expressed
in six cell lines. Mcl-1 was detected in BxPC-3, MIA PaCa-2, Capan-2,
and Panc-1 cells, and was weakly expressed in HPAF-II, but was not
detected in AsPc-1 cells.
3.2. Simultaneous knock-down of Bcl-xL and Mcl-1 strongly induces
apoptosis in PaCa cells
We next investigated the importance of speciﬁc anti-apoptotic Bcl-2
family proteins on PaCa cell survival. First, we transfected PaCa cells
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reduced their protein expression in three PaCa cell lines (Fig. 2A). Mcl-1
knock-down resulted in signiﬁcant induction of DNA fragmentation inFig. 2. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis in PaCa cells. BxPC-3, M
Bcl-xL for 24 h and the expression of these proteins was conﬁrmed by Western blot (A). DNA
measured by Cell Death ELISA and Hoechst 33258 staining, respectively. Arrowheads indicat
and nuclear fragmentation. Results are representative of three independent experiments and a
with siRNA against Mcl-1 and Bcl-xL for 24 h, after which DNA fragmentation was quantiﬁed
presented as mean ± SD (bars). *p b 0.05.BxPC-3 and MIA PaCa-2 cells, but this effect was not detected in Panc-
1 cells (Fig. 2B). On the other hand, down-regulation of Bcl-2 or Bcl-xL
protein expression had no measurable effect on inducing apoptosis inIA PaCa-2, and Panc-1 cells were transiently transfected with siRNA against Mcl-1, Bcl-2,
fragmentation (B) and changes in nuclear morphology (C) after siRNA transfection were
e apoptotic cells characterized by morphologic changes such as chromatin condensation
re presented asmean ± SD (bars). *p b 0.05. **p b 0.01. (D) AsPC-1 cells were transfected
by Cell Death ELISA. Results are representative of three independent experiments and are
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very strongly induced DNA fragmentation in all cell lines (Fig. 2B). In
contrast, simultaneous knock-down of Bcl-xL and Bcl-2 (data not
shown) or Mcl-1 and Bcl-2 had no additional effect over Mcl-1 knock-
down alone. We further conﬁrmed that simultaneous knock-down of
Bcl-xL and Mcl-1 induced apoptosis by detecting typical nuclear mor-
phological changes, such as chromatin condensation and nuclear frag-
mentation, consistent with apoptosis (Fig. 2C). These results indicate
that Bcl-xL and Mcl-1 cooperatively play a critical role in apoptotic cell
death in PaCa cells. We next knocked down Bcl-xL and Mcl-1 proteins
in AsPC-1 cells, since the AsPc-1 cells have no detectable Mcl-1 protein.
As shown in Fig. 2D, Bcl-xL knock-down resulted in signiﬁcant induction
of DNA fragmentation in AsPC-1 cells, but this effectwasnot detected by
Mcl-1 knock-down. This result further indicates that Bcl-xL and Mcl-1
cooperatively play a role in apoptotic cell death.
3.3. The effect of Bcl-xL and/or Mcl-1 knock-down on gemcitabine-induced
apoptosis in pancreatic cancer cells
It has been reported that Bcl-xL or Mcl-1 knock-down reinforces
chemotherapeutic drug-induced apoptosis in several cancers, including
PaCa [13,14]. Hence, we examined whether Bcl-xL and/or Mcl-1 knock-
down sensitizes PaCa cells to gemcitabine. As shown in Fig. 3A,
gemcitabine (1 μg/ml) had apoptosis-inducing effect in BxPC-3 cells,
but the effect was much weaker in MIA PaCa-2 cells. Knock-down of
Bcl-xL had no effect on apoptosis in untreated MIA PaCa-2 cells, but
slightly enhanced the cell death-inducing effects of gemcitabine in thisFig. 3. The effect of Bcl-xL and/or Mcl-1 knock-down on gemcitabine-induced apoptosis in PaC
treated with 1 μg/ml gemcitabine for further 72 h. DNA fragmentation and the cleavage of P
are representative of three independent experiments and are presented as mean ± SD (bars).cell line (Fig. 3A). Bcl-xL knock-down had no effect in untreated and
gemcitabine-treated BxPC-3 cells. Mcl-1 knock-down alone showed a
more robust apoptosis-inducing effect than Bcl-xL knock-down plus
gemcitabine in both cells. However, Mcl-1 knock-down did not enhance
gemcitabine toxicity in both cells. Simultaneous knock-down of Bcl-xL
and Mcl-1 induced apoptosis substantially, and this effect was much
more robust than gemcitabine plus Bcl-xL or Mcl-1 knock-down. How-
ever, again, adding gemcitabine to cells, in which Mcl-1 and Bcl-xL are
downregulated, had no further effect on apoptosis (Fig. 3A). These ef-
fects were also conﬁrmed by Western blot (Fig. 3B) detecting total and
cleaved PARP.
3.4. The apoptosis inducing effect of simultaneous knock-down of Bcl-xL
and Mcl-1 is mediated through mitochondrial cytochrome c release and
caspase activation
Having demonstrated that simultaneous knock-down of Bcl-xL/Mcl-1
by siRNA strongly induced apoptosis in PaCa cells, we next investigated
whether this effect wasmediated by activation of caspases. As shown in
Fig. 4A Bcl-xL or Mcl-1 knock-down induced cleavages of caspase-7 and
PARP in BxPC-3 and MIA PaCa-2 cells. No effect on caspase-3 cleavage
could be observed. However, Bcl-xL/Mcl-1 combined knock-down
strongly induced cleavages of caspase-3, -7, and PARP in both cell
lines, consistent with the results about DNA fragmentation (Fig. 2B, C).
Furthermore, the pan-caspase inhibitor zVAD-fmk (100 μM) completely
reversed Bcl-xL/Mcl-1 knock-down-induced DNA fragmentation as well
as the cleavage of PARP in both cell lines (Fig. 4B). Because it has beena. Cells were transfected with Bcl-xL and/or Mcl-1 siRNA for 24 h, after which cells were
ARP were quantiﬁed by Cell Death ELISA (A) and Western blot (B), respectively. Results
*p b 0.05.
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Mcl-1 expression in this setting. Treatment with zVAD-fmk only very
minimally increased Mcl-1 protein expression in Bcl-xL/Mcl-1 siRNA-Fig. 4. The apoptosis-inducing effect of simultaneous knock-down of Bcl-xL and Mcl-1 is media
transfectedwith Bcl-xL or/andMcl-1 siRNA for 24 h, afterwhich the cleavages of caspase-3, -7,
experiments. (B) Cells were treated with the pan-caspase inhibitor zVAD-fmk (100 μM) for 1 h
which the extent of apoptosis was quantiﬁed by Cell Death ELISA. Results are representative
Furthermore, PARP cleavage and the expression of Bcl-xL and Mcl-1 were also measured by W
mitochondrial membrane and cytosolic fractions were separated as described inMaterials and
cox-IV (cytochrome oxidase IV) was used as a loading control. Results are representative of th
measured by densitometry (right panel).treated BxPC-3 cells (but not in MIA PaCa-2 cells), indicating that Mcl-
1 protein down-regulation is almost exclusively achieved by RNA
interference and not by caspase-mediated cleavage. Since cytochrometed throughmitochondria and caspases. (A) BxPC-3 andMIA PaCa-2 cells were transiently
and PARPweremeasured byWestern blot. Results are representative of three independent
, and then were transiently transfected with control or Bcl-xL/Mcl-1 siRNA for 24 h, after
of three independent experiments and are presented as mean ± SD (bars). *p b 0.005.
estern blot. (C) Cells were transfected with Bcl-xL and Mcl-1 siRNA for 24 h, after which
methods. Cytochrome c localization wasmeasured byWestern blot. Mitochondrial marker
ree independent experiments. To make the translocation of proteins clear, each blots are
2985H. Takahashi et al. / Biochimica et Biophysica Acta 1833 (2013) 2980–2987c release into the cytosol is the key event in apoptosis, which leads to the
activation of downstream caspases, we next investigated the release of
cytochrome c. Bcl-xL/Mcl-1 knock-down induced cytochrome c release
from the mitochondria (as evident by a decrease of mitochondrial
cytochrome c and an increase in cytosolic cytochrome c) in both cells
(Fig. 4C).
3.5. Bax knock-down diminishes the effect of simultaneous knock-down of
Bcl-xL and Mcl-1 on apoptosis in pancreatic cancer cells
Since activation of the multi-domain molecule Bax (conformational
change, mitochondrial translocation, and oligomerization) leads to cy-
tochrome c release from mitochondria [16], we decided to investigate
the effect of Bcl-xL/Mcl-1 knock-down on Bax activation. In this regard,
we ﬁrst measured the effect of Bcl-xL/Mcl-1 knock-down on Bax
expression. As shown in Fig. 5A, Bcl-xL/Mcl-1 knock-down did not
change Bax expression in whole cell lysates. Next, we investigated
whether Bcl-xL/Mcl-1 knock-down induces Bax mitochondrial translo-
cation. As shown in Fig. 5B, Bcl-xL/Mcl-1 knock-down clearly induced
Bax translocation from the cytosol to the mitochondria in both cell
lines. To further conﬁrm the importance of Bax on apoptosis induced
by Bcl-xL/Mcl-1 knock-down, we used siRNA against Bax. Bax knock-Fig. 5.Activation of Bax correlateswith apoptosis induced by simultaneous knock-down of Bcl-x
24 h, after which the Bax expression was measured by Western blot. Results are representat
against Bcl-xL and Mcl-1 for 24 h, after whichmitochondrial membrane and cytosolic fraction w
byWestern blot. Results are representative of three independent experiments. Tomake the tran
were ﬁrst transfectedwith Bax siRNA for 24 h, after which cells were transfectedwith siRNA ag
expression (right panel) was measured. Results are representative of three independent experdown partially reversed the induction of apoptosis by Bcl-xL/Mcl-1
knock-down (Fig. 5C), indicating that Bax activation may be responsi-
ble, at least in part, for the dramatic induction of apoptosis by the simul-
taneous knock-down of Bcl-xL and Mcl-1.
4. Discussion
One reason for the dismal prognosis of patientswith PaCa and the in-
efﬁciency of most chemo- and radio-therapeutic regimens is the strong
resistance of PaCa cells to cell death. Anti-apoptotic Bcl-2 family pro-
teins have been reported to protect cells from death stimuli in several
cancer models. In this regard, we previously reported that Mcl-1 is an
important factor in PaCa cell survival [2]. However, Mcl-1 knock-down
failed to increase cell death in Panc-1 cells in this and a previous report
[17], suggesting that additional factors may be important as well. In this
study, we provide strong evidence that Mcl-1 and Bcl-xL, and not Bcl-2,
play a critical role in PaCa cell deathmechanisms. This resultwas consis-
tent with previous reports that simultaneous knock-down of Bcl-xL and
Mcl-1 by siRNA resulted in marked induction of apoptosis in chemo-
resistant ovarian carcinoma andmethothelioma cell lines [18,19]. How-
ever, no report has to our knowledge described the efﬁcacy of simulta-
neous knockdown of Bcl-2 family proteins in pancreatic cancer cells.L andMcl-1. (A) Cells were transiently transfectedwith siRNA against Bcl-xL andMcl-1 for
ive of three independent experiments. (B) Cells were transiently transfected with siRNA
ere separated as described inMaterials and methods. Bax expression was thenmeasured
slocation of proteins clear, each blots aremeasured by densitometry (right panel). (C) Cells
ainst Bcl-xL andMcl-1 for further 24 h. The extent of apoptosis (left panel) and Bax protein
iments and are presented as mean ± SD (bars). *p b 0.05.
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icantly induces apoptotic cell death in pancreatic cancer cells through a
Bax-mediated mechanism. But, how does Bcl-xL and Mcl-1 knockdown
induce Bax translocation? Bax is a strong multi-domain pro-apoptotic
protein that resides in the cytoplasm as inactive monomer in healthy
cells. Upon apoptotic stimuli, Bax undergoes conformational change
leading to translocation from cytoplasm to mitochondria [20]. Similar
to our results, it has been reported that Mcl-1 knock-down by siRNA
induced Bax translocation to mitochondria in oral squamous cell carci-
noma cells [21]. These results indicated that the loss of Mcl-1 itself can
modulate the subcellular distribution of Bax. In this regard, activator
BH3-only proteins, especially Bim and Bid, might play an important
role. It has been reported that activator BH3-only proteins can bind
both Bcl-xL and Mcl-1, and activator BH3-only proteins that were
freed from Bcl-xL and Mcl-1 can directly activate Bax [22].
However, the effect of Bax knock-down on reversing apoptosis
induced by Bcl-xL/Mcl-1 knockdown was only partial. Previous reports
using BH3-mimetics (e.g. ABT-737 and obatoclax) showed that Mcl-1
and Bcl-xL cooperate to sequester the pro-apoptotic multidomain
protein Bak and prevent its activation [23,24]. Since we conﬁrmed
that Bak binds with Bcl-xL and Mcl-1 on the mitochondrial membrane
in BxPC-3 and MIA Paca-2 cells [2], it is plausible that Bak, as well as
Bax (as shown in the present study), might play an important role.
It has been reported that anti-apoptotic Bcl-2 family proteins control
Bak and Bax activation by direct or indirect mechanisms in cooperation
with BH3-only proteins [3]. In the indirectmodel, Bcl-xL andMcl-1 bind
to Bak not Bax inmouse embryo ﬁbroblast (MEF) cells. Cytotoxic signals
activate a combination of BH3-only proteins that can displace Bak from
Bcl-xL and Mcl-1 to undergo conformational changes required for Bak
activation. In the direct model, activator BH3-only proteins can directly
bind and activate Bak or Bax. On the other hand, anti-apoptotic proteins
also can bind to activator BH3-only proteins as well as sensitizer BH3-
only proteins. Thus, the degree to which BH3-only proteins ultimately
inﬂuence cellular apoptosis appears to be dependent on the delicate
balance between anti-apoptotic proteins and the BH3-only proteins. In
this regard, genetic knock-down of Bcl-xL and Mcl-1, as well as BH3-
mimetic molecules, seems to be a promising approach in PaCa cells. In
this report, we showed the endogenous expression and localization of
anti-apoptotic Bcl-2 family proteins. Bcl-xL and Mcl-1 were highly
expressed in PaCa cell lines, while Bcl-2 was detected only in MIA
PaCa-2 and Panc-1 cells. Similar to our results, the expression of Bcl-2,
Bcl-xL, and Mcl-1 in human PaCa tissues was reported at 23–25%, 90%,
and 90%, respectively [25]. This also suggests that Bcl-xL and Mcl-1,
but not Bcl-2, may be an intriguing therapeutic target in PaCa.
Anti-apoptotic Bcl-2 family proteins have been reported to correlate
with chemo-resistance in human malignancies [26,27]. In contrast to
our data, Wei and colleagues reported that Mcl-1 down-regulation en-
hanced the chemo-sensitivity to gemcitabine in PaCa cells [28]. Howev-
er, our data demonstrated that gemcitabine could not augment the cell
death induced by the knockdown of Mcl-1 and/or Mcl-1/Bcl-xL. It may
be caused by different levels of down-regulation of Mcl-1 protein in
both studies. Simultaneous knock-down of Bcl-xL andMcl-1was clearly
superior in inducing apoptosis than gemcitabine alone or a combination
of gemcitabine with a knock-down of a single anti-apoptotic protein.
These results indicate that Bcl-xL andMcl-1maybe bonaﬁde therapeutic
targets in pancreatic cancer independent of gemcitabine and may not
only function as chemo-sensitizers.
Today, some therapeutic approaches have been reported to be
aimed at abrogating the protective function of anti-apoptotic Bcl-2 fam-
ily proteins. It has been described that certain BH3-mimetics can bind to
and functionally inhibit Bcl-2 family proteins. The Bcl-2 antagonist ABT-
737 targets Bcl-2 and Bcl-xL, but notMcl-1,whichmay confer resistance
to this agent. Down-regulation of Mcl-1 by siRNA or pharmaceutical
drugs has been reported to potentiate ABT-737 lethality in human leu-
kemia and melanoma cells [23,29]. Similarly, Okumura et al. reported
that Noxa induction sensitizes Mcl-1 expressing human colorectalcancer cells to ABT-737 [30]. Another pan-Bcl-2 inhibitor, obatoclax
(GX15-070) has also been reported to antagonize Mcl-1 and overcome
Mcl-1 mediated resistance to apoptosis [24]. These observations are in
accordancewith our results showing that Bcl-xL andMcl-1 cooperative-
ly play a critical role in pancreatic cancer cell apoptosis. In addition to
small molecule drugs, siRNA-based therapy is another promising thera-
peutic approach. Although the design and delivery system of siRNAs has
not been established yet [31], siRNA based therapy has made remark-
able progress and siRNA-based therapy in vivo has been reported in
recent years [32–34].
In summary, these ﬁndings reinforce the notion that disruption of a
single anti-apoptotic protein, i.e. Bcl-xL or Mcl-1, may not be optimal
for efﬁciently inducing cell death in pancreatic cancer cells. Instead,
our data clearly suggest that reducing the expression of both anti-
apoptotic proteins should be the goal.
Acknowledgement
This work was supported by the National Institutes of Health
(P01AT003960, P01CA163200, R01CA122042), the Hirshberg Founda-
tion for Pancreatic Cancer Research and the JSPS KAKENHI Grant num-
ber 24592036.
References
[1] H.S. Hochster, D.G. Haller, A. de Gramont, J.D. Berlin, P.A. Philip, M.J. Moore, J.A. Ajani,
Consensus report of the international society of gastrointestinal oncology on thera-
peutic progress in advanced pancreatic cancer, Cancer 107 (2006) 676–685.
[2] H. Takahashi, M.C. Chen, H. Pham, E. Angst, J.C. King, J. Park, E.Y. Brovman, H.
Ishiguro, D.M. Harris, H.A. Reber, O.J. Hines, A.S. Gukovskaya, V.L. Go, G. Eibl,
Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1
down-regulation in human pancreatic cancer cells, Biochim. Biophys. Acta 1813
(2011) 1465–1474.
[3] N.N. Danial, BCL-2 family proteins: critical checkpoints of apoptotic cell death, Clin.
Cancer Res. 13 (2007) 7254–7263.
[4] D.Westphal, G. Dewson, P.E. Czabotar, R.M. Kluck, Molecular biology of Bax and Bak
activation and action, Biochim. Biophys. Acta 1813 (2011) 521–531.
[5] S.N. Willis, L. Chen, G. Dewson, A. Wei, E. Naik, J.I. Fletcher, J.M. Adams, D.C. Huang,
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced
by BH3-only proteins, Genes Dev. 19 (2005) 1294–1305.
[6] M.F. van Delft, A.H. Wei, K.D. Mason, C.J. Vandenberg, L. Chen, P.E. Czabotar, S.N.
Willis, C.L. Scott, C.L. Day, S. Cory, J.M. Adams, A.W. Roberts, D.C. Huang, The BH3
mimetic ABT-737 targets selective Bcl-2 proteins and efﬁciently induces apoptosis
via Bak/Bax if Mcl-1 is neutralized, Cancer Cell 10 (2006) 389–399.
[7] G. Eibl, Y. Takata, L.G. Boros, J. Liu, Y. Okada, H.A. Reber, O.J. Hines, Growth stimulation
of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor, Cancer Res. 65
(2005) 982–990.
[8] G. Eibl, H.A. Reber, M.N. Wente, O.J. Hines, The selective cyclooxygenase-2 inhibitor
nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2,
Pancreas 26 (2003) 33–41.
[9] E. Angst, H.A. Reber, O.J. Hines, G. Eibl,Mononuclear cell-derived interleukin-1beta con-
fers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2,
Surgery 144 (2008) 57–65.
[10] H. Takahashi, A. Li, D.W. Dawson, O.J. Hines, H.A. Reber, G. Eibl, Cyclooxygenase-2
confers growth advantage to syngeneic pancreatic cancer cells, Pancreas 40 (2011)
453–459.
[11] J.K. Brunelle, A. Letai, Control of mitochondrial apoptosis by the Bcl-2 family, J. Cell
Sci. 122 (2009) 437–441.
[12] M.S. Ola, M. Nawaz, H. Ahsan, Role of Bcl-2 family proteins and caspases in the
regulation of apoptosis, Mol. Cell. Biochem. 351 (2011) 41–58.
[13] S. Banerjee, M. Choi, A. Aboukameel, Z. Wang, M. Mohammad, J. Chen, D. Yang, F.H.
Sarkar, R.M. Mohammad, Preclinical studies of apogossypolone, a novel pan inhibi-
tor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in
pancreatic cancer cells, Pancreas 39 (2010) 323–331.
[14] X. Lei, Z. Huang, M. Zhong, B. Zhu, S. Tang, D. Liao, Bcl-XL small interfering RNA sen-
sitizes cisplatin-resistant human lung adenocarcinoma cells, Acta Biochim. Biophys.
Sin. (Shanghai) 39 (2007) 344–350.
[15] C.Weng, Y. Li, D. Xu, Y. Shi, H. Tang, Speciﬁc cleavage of Mcl-1 by caspase-3 in tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in
Jurkat leukemia T cells, J. Biol. Chem. 280 (2005) 10491–10500.
[16] E. Er, L. Oliver, P.F. Cartron, P. Juin, S. Manon, F.M. Vallette, Mitochondria as the target
of the pro-apoptotic protein Bax, Biochim. Biophys. Acta 1757 (2006) 1301–1311.
[17] S. Huang, F.A. Sinicrope, BH3 mimetic ABT-737 potentiates TRAIL-mediated apopto-
tic signaling by unsequestering Bim and Bak in human pancreatic cancer cells,
Cancer Res. 68 (2008) 2944–2951.
[18] E. Brotin, M. Meryet-Figuière, K. Simonin, R.E. Duval, M. Villedieu, J. Leroy-Dudal, E.
Saison-Behmoaras, P. Gauduchon, C. Denoyelle, L. Poulain, Bcl-xL and MCL-1 consti-
tute pertinent targets in ovarian carcinoma and their concomitant inhibition is
sufﬁcient to induce apoptosis, Int. J. Cancer 126 (2010) 885–895.
2987H. Takahashi et al. / Biochimica et Biophysica Acta 1833 (2013) 2980–2987[19] E. Varin, C. Denoyelle, E. Brotin, M.Meryet-Figuière, F. Giffard, E. Abeilard, D. Goux, P.
Gauduchon, P. Icard, L. Poulain, Downregulation of Bcl-xL and Mcl-1 is sufﬁcient to
induce cell death in mesothelioma cells highly refractory to conventional chemo-
therapy, Carcinogenesis 31 (2010) 984–993.
[20] J. Haneef, P. M., R.S.K. Thankayyan, H. Sithul, S. Sreeharshan, Bax translocation medi-
atedmitochondrial apoptosis and caspase dependent photosensitizing effect of Ficus
religiosa on cancer cells, PLoS One 7 (2012) e40055.
[21] J.A. Shin, J.Y. Jung, M.H. Ryu, S. Safe, S.D. Cho, Mithramycin A inhibits myeloid cell
leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xeno-
graft through activation of Bax and oligomerization, Mol. Pharmacol. 83 (2013)
33–41.
[22] H. Du, J. Wolf, B. Schafer, T. Moldoveanu, J.E. Chipuk, T. Kuwana, BH3 domains other
than Bim and Bid can directly activate Bax/Bak, J. Biol. Chem. 286 (2011) 491–501.
[23] S. Chen, Y. Dai, H. Harada, P. Dent, S. Grant, Mcl-1 down-regulation potentiates
ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation,
Cancer Res. 67 (2007) 782–791.
[24] M. Nguyen, R.C. Marcellus, A. Roulston, M. Watson, L. Serfass, S.R. Murthy Madiraju,
D. Goulet, J. Viallet, L. Bélec, X. Billot, S. Acoca, E. Purisima, A. Wiegmans, L. Cluse,
R.W. Johnstone, P. Beauparlant, G.C. Shore, Small molecule obatoclax (GX15-070)
antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis, Proc.
Natl. Acad. Sci. U. S. A. 104 (2007) 19512–19517.
[25] Y. Miyamoto, R. Hosotani, M. Wada, J.U. Lee, T. Koshiba, K. Fujimoto, S. Tsuji, S.
Nakajima, R. Doi, M. Kato, Y. Shimada, M. Imamura, Immunohistochemical analysis
of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers, Oncology 56 (1999)
73–82.
[26] D. Karnak, L. Xu, Chemosensitization of prostate cancer by modulating Bcl-2 family
proteins, Curr. Drug Targets 11 (2010) 699–707.
[27] T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M.
Bruncko, T.L. Deckwerth, J. Dinges, P.J. Hajduk, M.K. Joseph, S. Kitada, S.J. Korsmeyer,A.R. Kunzer, A. Letai, C. Li, M.J. Mitten, D.G. Nettesheim, S. Ng, P.M. Nimmer,
J.M. O'Connor, A. Oleksijew, A.M. Petros, J.C. Reed, W. Shen, S.K. Tahir, C.B.
Thompson, K.J. Tomaselli, B. Wang, M.D. Wendt, H. Zhang, S.W. Fesik, S.H.
Rosenberg, An inhibitor of Bcl-2 family proteins induces regression of solid tu-
mours, Nature 435 (2005) 677–681.
[28] S.H. Wei, K. Dong, F. Lin, X. Wang, B. Li, J.J. Shen, Q. Zhang, R. Wang, H.Z. Zhang,
Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA inter-
ference targeting Mcl-1 gene in pancreatic carcinoma cell, Cancer Chemother.
Pharmacol. 62 (2008) 1055–1064.
[29] A.M. Keuling, K.E. Felton, A.A. Parker,M. Akbari, S.E. Andrew, V.A. Tron, RNA silencing
of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-
8-dependent pathway, PLoS One 4 (2009) e6651.
[30] K. Okumura, S. Huang, F.A. Sinicrope, Induction of Noxa sensitizes human colorectal
cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737,
Clin. Cancer Res. 14 (2008) 8132–8142.
[31] S. He, D. Zhang, F. Cheng, F. Gong, Y. Guo, Applications of RNA interference in cancer
therapeutics as a powerful tool for suppressing gene expression, Mol. Biol. Rep. 36
(2009) 2153–2163.
[32] Y. Liang, H. Gao, S.Y. Lin, J.A. Goss, F.C. Brunicardi, K. Li, siRNA-based targeting of
cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor
development in breast cancer mouse model, PLoS One 5 (2010) e12860.
[33] M. Wei, L. Zhu, Y. Li, W. Chen, B. Han, Z. Wang, J. He, H. Yao, Z. Yang, Q. Zhang, B. Liu,
Q. Gu, Z. Zhu, K. Shen, Knocking down cyclin D1b inhibits breast cancer cell growth
and suppresses tumor development in a breast cancer model, Cancer Sci. 102
(2011) 1537–1544.
[34] I. Takigami, T. Ohno, Y. Kitade, A. Hara, A. Nagano, G. Kawai, M. Saitou, A.
Matsuhashi, K. Yamada, K. Shimizu, Synthetic siRNA targeting the breakpoint of
EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model, Int. J.
Cancer 128 (2011) 216–226.
